Selvita Establishes its UK Subsidiary in Cambridge

Selvita, a global drug discovery company with offices in the US and Poland, is opening its first office in the UK. The office is based in Cambridge, considered to be one of the most significant biotechnology clusters in the world. The new office will be responsible for supporting the ongoing projects for the customers from the UK and Northern Ireland, as well as seeking new collaboration opportunities in the area of integrated drug discovery services with pharma and biotech companies in the region. Selvita Ltd will be focused on supporting and developing business relationships with local partners whereas Selvita’s laboratories remain in Krakow, Poland.

“Selvita laboratories are currently located at 20 000 sq. ft. in a modern life science park in Krakow, Poland. We continuously invest in top-class equipment and employ highly skilled professionals with experience from some of the most renowned pharmaceutical companies in Western Europe and the US. This sets us among the biggest and the most innovative contract research providers in Central and Eastern Europe. Our location in Poland allows us to offer our clients significant cost efficiencies compared to other geographies. We decided to establish direct presence in the UK, to be closer to our business partners located in the UK,” said Dr Milosz Gruca, CEO at Selvita UK.

The UK is the third largest global R&D market. Biotechnology clusters are springing up around the country. Drug innovators seek out the high quality contract service providers mainly because it translates to accessing additional skillsets and reduced internal costs. Selvita, whose mission is to help their partners to maximize productivity and lower costs of product development, is glad to become a part of this environment.

“I am excited that Selvita is establishing its presence in Cambridge — home to the leading scientific organizations. This step will allow us to become more visible on the local market and remain at full disposal of our UK-based customers. I strongly believe that Selvita can become a valuable partner for many leading pharmaceutical and biotechnology companies in the UK and Northern Ireland,” said Alicja Malysiak, Vice President of Sales at Selvita UK.